共 184 条
[1]
Dellapasqua S(2005)The choice of systemic adjuvant therapy in receptor-positive early breast cancer Eur J Cancer 41 357-364
[2]
Castiglione-Gertsch M(2003)Aromatase inhibitors in breast cancer N Engl J Med 348 2431-2442
[3]
Smith IE(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-717
[4]
Dowsett M(2009)Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766-776
[5]
Mouridsen H(2008)Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45-53
[6]
Giobbie-Hurder A(2011)Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial Lancet 377 321-331
[7]
Goldhirsch A(2006)Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633-643
[8]
Thürlimann B(1995)The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women J Clin Endocrinol Metab 80 3191-3195
[9]
Paridaens R(2008)Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials Cancer 112 260-267
[10]
Smith I(2017)Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis JNCI: J National Cancer Inst 110 31-9